2,810 Becton, Dickinson and Company $BDX Shares Purchased by Cardinal Capital Management

Cardinal Capital Management lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 8.3% in the third quarter, HoldingsChannel.com reports. The fund owned 36,780 shares of the medical instruments supplier’s stock after purchasing an additional 2,810 shares during the period. Cardinal Capital Management’s holdings in Becton, Dickinson and Company were worth $6,584,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Maryland Capital Advisors Inc. lifted its position in Becton, Dickinson and Company by 13,900.0% during the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 139 shares during the period. SHP Wealth Management purchased a new stake in Becton, Dickinson and Company in the fourth quarter worth approximately $26,000. Meeder Asset Management Inc. boosted its holdings in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD bought a new stake in Becton, Dickinson and Company in the 1st quarter worth approximately $29,000. Finally, Bell Investment Advisors Inc bought a new stake in Becton, Dickinson and Company in the 2nd quarter worth approximately $29,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BDX. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. UBS Group started coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target on the stock. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Wolfe Research assumed coverage on Becton, Dickinson and Company in a research report on Tuesday. They set an “outperform” rating for the company. Finally, Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $185.07.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $194.29 on Thursday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $195.99. The firm has a market capitalization of $53.53 billion, a price-to-earnings ratio of 58.52, a price-to-earnings-growth ratio of 13.07 and a beta of 0.21. The firm has a 50 day moving average of $184.73 and a 200 day moving average of $164.54.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Insider Buying and Selling

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 6,906 shares of company stock valued at $1,265,855. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.